Literature DB >> 23813842

NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice.

Alexander Wree1, Akiko Eguchi, Matthew D McGeough, Carla A Pena, Casey D Johnson, Ali Canbay, Hal M Hoffman, Ariel E Feldstein.   

Abstract

UNLABELLED: Inflammasome activation plays a central role in the development of drug-induced and obesity-associated liver disease. However, the sources and mechanisms of inflammasome-mediated liver damage remain poorly understood. Our aim was to investigate the effect of NLRP3 inflammasome activation on the liver using novel mouse models. We generated global and myeloid cell-specific conditional mutant Nlrp3 knock-in mice expressing the D301N Nlrp3 mutation (ortholog of D303N in human NLRP3), resulting in a hyperactive NLRP3. To study the presence and significance of NLRP3-initiated pyroptotic cell death, we separated hepatocytes from nonparenchymal cells and developed a novel flow-cytometry-based (fluorescence-activated cell sorting; FACS) strategy to detect and quantify pyroptosis in vivo based on detection of active caspase 1 (Casp1)- and propidium iodide (PI)-positive cells. Liver inflammation was quantified histologically by FACS and gene expression analysis. Liver fibrosis was assessed by Sirius Red staining and quantitative polymerase chain reaction for markers of hepatic stellate cell (HSC) activation. NLRP3 activation resulted in shortened survival, poor growth, and severe liver inflammation; characterized by neutrophilic infiltration and HSC activation with collagen deposition in the liver. These changes were partially attenuated by treatment with anakinra, an interleukin-1 receptor antagonist. Notably, hepatocytes from global Nlrp3-mutant mice showed marked hepatocyte pyroptotic cell death, with more than a 5-fold increase in active Casp1/PI double-positive cells. Myeloid cell-restricted mutant NLRP3 activation resulted in a less-severe liver phenotype in the absence of detectable pyroptotic hepatocyte cell death.
CONCLUSIONS: Our data demonstrate that global and, to a lesser extent, myeloid-specific NLRP3 inflammasome activation results in severe liver inflammation and fibrosis while identifying hepatocyte pyroptotic cell death as a novel mechanism of NLRP3-mediated liver damage.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23813842      PMCID: PMC4008151          DOI: 10.1002/hep.26592

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

1.  Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice.

Authors:  Jan Petrasek; Angela Dolganiuc; Timea Csak; Evelyn A Kurt-Jones; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2010-08-19       Impact factor: 22.682

2.  The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock.

Authors:  Wei Shao; Garabet Yeretssian; Karine Doiron; Sabah N Hussain; Maya Saleh
Journal:  J Biol Chem       Date:  2007-10-24       Impact factor: 5.157

3.  Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages.

Authors:  Susan L Fink; Brad T Cookson
Journal:  Cell Microbiol       Date:  2006-07-04       Impact factor: 3.715

4.  Inflammasome-mediated regulation of hepatic stellate cells.

Authors:  Azuma Watanabe; Muhammad Adnan Sohail; Dawidson Assis Gomes; Ardeshir Hashmi; Jun Nagata; Fayyaz Shiraz Sutterwala; Shamail Mahmood; Muhammad Nauman Jhandier; Yan Shi; Richard Anthony Flavell; Wajahat Zafar Mehal
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-09       Impact factor: 4.052

5.  Interleukin-1 participates in the progression from liver injury to fibrosis.

Authors:  Roben G Gieling; Karen Wallace; Yuan-Ping Han
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-02       Impact factor: 4.052

6.  Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.

Authors:  Susannah D Brydges; James L Mueller; Matthew D McGeough; Carla A Pena; Amirhossein Misaghi; Chhavi Gandhi; Chris D Putnam; David L Boyle; Gary S Firestein; Anthony A Horner; Pejman Soroosh; Wendy T Watford; John J O'Shea; Daniel L Kastner; Hal M Hoffman
Journal:  Immunity       Date:  2009-06-04       Impact factor: 31.745

7.  Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.

Authors:  Rafal P Witek; W Carl Stone; F Gamze Karaca; Wing-Kin Syn; Thiago A Pereira; Kolade M Agboola; Alessia Omenetti; Youngmi Jung; Vanessa Teaberry; Steve S Choi; Cynthia D Guy; John Pollard; Peter Charlton; Anna Mae Diehl
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

8.  DAMPs ramp up drug toxicity.

Authors:  Jacquelyn J Maher
Journal:  J Clin Invest       Date:  2009-02       Impact factor: 14.808

9.  Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome.

Authors:  Avlin B Imaeda; Azuma Watanabe; Muhammad A Sohail; Shamail Mahmood; Mehdi Mohamadnejad; Fayyaz S Sutterwala; Richard A Flavell; Wajahat Z Mehal
Journal:  J Clin Invest       Date:  2009-01-26       Impact factor: 14.808

10.  Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria.

Authors:  Edward A Miao; Irina A Leaf; Piper M Treuting; Dat P Mao; Monica Dors; Anasuya Sarkar; Sarah E Warren; Mark D Wewers; Alan Aderem
Journal:  Nat Immunol       Date:  2010-11-07       Impact factor: 25.606

View more
  269 in total

Review 1.  Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Alexander Wree; Wajahat Z Mehal; Ariel E Feldstein
Journal:  Semin Liver Dis       Date:  2016-02-12       Impact factor: 6.115

Review 2.  Role of innate immune system in systemic sclerosis.

Authors:  Nicola Fullard; Steven O'Reilly
Journal:  Semin Immunopathol       Date:  2015-07-10       Impact factor: 9.623

3.  Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.

Authors:  Wenqi Yang; Ling Liu; Yuan Wei; Chunlu Fang; Shujing Liu; Fu Zhou; Yaping Li; Ge Zhao; Ziyi Guo; Yuan Luo; Liangming Li
Journal:  Lab Invest       Date:  2020-12-02       Impact factor: 5.662

4.  Enalapril inhibits tubulointerstitial inflammation and NLRP3 inflammasome expression in BSA-overload nephropathy of rats.

Authors:  Li-hong Ding; Dan Liu; Min Xu; Hong Liu; Min Wu; Ri-ning Tang; Lin-li Lv; Kun-ling Ma; Bi-cheng Liu
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

5.  NLRP3 inflammasome as a novel target for docosahexaenoic acid metabolites to abrogate glomerular injury.

Authors:  Guangbi Li; Zhida Chen; Owais M Bhat; Qinghua Zhang; Justine M Abais-Battad; Sabena M Conley; Joseph K Ritter; Pin-Lan Li
Journal:  J Lipid Res       Date:  2017-04-12       Impact factor: 5.922

6.  Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH.

Authors:  George N Ioannou; Savitha Subramanian; Alan Chait; W Geoffrey Haigh; Matthew M Yeh; Geoffrey C Farrell; Sum P Lee; Christopher Savard
Journal:  J Lipid Res       Date:  2017-04-12       Impact factor: 5.922

7.  Inflammasome-mediated inflammation and fibrosis: It is more than just the IL-1β.

Authors:  Muhammad Amir; Mark J Czaja
Journal:  Hepatology       Date:  2017-12-23       Impact factor: 17.425

Review 8.  Lytic cell death in metabolic liver disease.

Authors:  Jérémie Gautheron; Gregory J Gores; Cecília M P Rodrigues
Journal:  J Hepatol       Date:  2020-04-13       Impact factor: 25.083

9.  Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.

Authors:  Resat Cinar; Malliga R Iyer; Ziyi Liu; Zongxian Cao; Tony Jourdan; Katalin Erdelyi; Grzegorz Godlewski; Gergő Szanda; Jie Liu; Joshua K Park; Bani Mukhopadhyay; Avi Z Rosenberg; Jeih-San Liow; Robin G Lorenz; Pal Pacher; Robert B Innis; George Kunos
Journal:  JCI Insight       Date:  2016-07-21

10.  NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice.

Authors:  Alexander Wree; Matthew D McGeough; Maria Eugenia Inzaugarat; Akiko Eguchi; Susanne Schuster; Casey D Johnson; Carla A Peña; Lukas J Geisler; Bettina G Papouchado; Hal M Hoffman; Ariel E Feldstein
Journal:  Hepatology       Date:  2017-12-28       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.